Page 1

Q2 FINANCIAL SUMMARY Figures within parentheses refer to the preceding year . Second quarter Net sales amounted to TEUR 115 ( 76 ) . Operating loss ( EBIT ) increased to TEUR 2,968 ( 1,103 ) . Loss after tax amounted to TEUR 2,875 ( 1,144 ) . ■ ■ ' Implantica INTERIM REPORT APR – JUN 2021 ■ Basic and diluted loss per Class A share amounted to EUR 0.04 ( 0.03 ) . Liquid funds as at the end of the period amounted to MEUR 147 SIGNIFICANT EVENTS In the second quarter of 2021 RefluxStop ™ is now being implemented at one of the largest hospitals in Europe , University Hospital AKH Vienna . Professor Schoppmann , one of Europe's leading anti reflux surgeons , began operations with RefluxStop ™ and is conducting a study with 25-30 reflux patients . TM In Sweden , which is Implantica's second home market , RefluxStop ™ M can be implanted with reimbursement by public healthcare . Discussions have been initiated with key centers in Sweden . Implantica has started to commercialize RefluxStop ™ on a reimbursed basis in Italy and Spain based on local and regional hospital agreements . Implantica successfully raised approximately SEK 600 million in a directed new share issue to speed up the commercialization of Reflux- Stop TM and to accelerate bringing our eHealth platform tecnology to the market . Implantica is reinforcing its management with additional important core competencies to build an even stronger team supporting the Company's future growth . RefluxStop TM achieves regulatory authorisation in New Zealand . Q221 INTERIM REPORT IMPLANTICA First six months Net sales amounted to TEUR 197 ( 99 ) . Operating loss ( EBIT ) increased to TEUR 5,247 ( 2,500 ) . Loss after tax amounted to TEUR 4,841 ( 2,396 ) . Basic and diluted loss per Class A share amounted to EUR 0.07 ( 0.05 ) . After the end of the period Klinikum Friedrichshafen , a prominent anti - reflux center in Germany , successfully completes several surgeries with RefluxStop ™ Implantica appoints new team to head commercial operations with two highly experienced sales and marketing professionals joining the company . Implantica strengthens its management team with a new VP Quality & Regulatory Affairs professional with over 20 years of global regulatory affairs experience . Implantica incorporates wholly owned subsidiary in the US , Implantica Inc. and has filed a supplement to the pre - submission for RefluxStop ™ with the FDA . Implantica announces that it will perform a downstream merger with its holding company , Implantica MediSwiss AG . The board has accepted a contribution of assets of EUR 120 million from the main shareholder to the reserves ( without monetary compensation ) and agreed to perform a stock split in the class B shares pending EGM decision on September 17 .